0000950170-23-071106.txt : 20231218 0000950170-23-071106.hdr.sgml : 20231218 20231218163014 ACCESSION NUMBER: 0000950170-23-071106 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231214 FILED AS OF DATE: 20231218 DATE AS OF CHANGE: 20231218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Keson-Brookes Maiken CENTRAL INDEX KEY: 0001693805 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41837 FILM NUMBER: 231494154 MAIL ADDRESS: STREET 1: 35 OAK HILL ROAD CITY: FAYVILLE STATE: MA ZIP: 01745 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mural Oncology plc CENTRAL INDEX KEY: 0001971543 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10 EARLSFORT TERRACE CITY: DUBLIN 2 STATE: L2 ZIP: D02 T380 BUSINESS PHONE: 353 1 905 8020 MAIL ADDRESS: STREET 1: 10 EARLSFORT TERRACE CITY: DUBLIN 2 STATE: L2 ZIP: D02 T380 FORMER COMPANY: FORMER CONFORMED NAME: Mural Oncology Ltd DATE OF NAME CHANGE: 20230403 FORMER COMPANY: FORMER CONFORMED NAME: Pistachiovale Ltd DATE OF NAME CHANGE: 20230329 4 1 ownership.xml 4 X0508 4 2023-12-14 0001971543 Mural Oncology plc MURA 0001693805 Keson-Brookes Maiken C/O MURAL ONCOLOGY PLC 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380 IRELAND false true false false See Remarks false Ordinary Shares 2023-12-14 4 A false 29207 0.00 A 29207 D Stock Option (right to buy) 3.61 2023-12-14 4 A false 54242 0.00 A 2033-12-13 Ordinary Shares 54242 54242 D Consists of ordinary shares issuable under 29,207 restricted stock units ("RSUs"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of July 17, 2023, subject to the reporting person's continued service with the Issuer. This option was granted on December 14, 2023. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on July 17, 2024 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer. Chief Legal Officer and Secretary /s/ Maiken Keson-Brookes 2023-12-18